Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Breast Cancer

Presenters

Seungtaek Lim

Citation

Annals of Oncology (2019) 30 (suppl_9): ix1-ix8. 10.1093/annonc/mdz416

Authors

S. Lim1, J. Sohn2, G. Kim2, Y. Moon3, J.H. Kim4

Author affiliations

  • 1 Hematooncology, Wonju Severance Christianity Hospital, 220-701 - Gangwon-do/KR
  • 2 Medical Oncology, Yonsei Cancer Center, 03722 - Seoul/KR
  • 3 Medical Oncology, Bundang Cha Hospital, 13496 - Bundang/KR
  • 4 Hematooncology, Gangnam Severance Hospital, 06273 - Seoul/KR
More

Resources

Abstract 10P

Background

There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment. There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment.

Methods

We identified patients who fulfilled inclusion criteria (curative surgery, <1cm, N0, and HER2(+) breast cancer) by medical chart review. We collected data of baseline characteristics, receptor status, surgical method, histologic type, histologic and nuclear grade, adjuvant treatment (chemotherapy, radiotherapy, endocrine therapy, and trastuzumab. We compared baseline characteristics between patients with or without adjuvant treatment (Chi-square), and the prognosis between them (Kaplan meier curve and log-rank test). SPSS version 18.0 was used for statistical analysis.

Results

A total of 429 patients (pT1a=205, pT1b=222) were identified. In patients with pT1a, only 1 patient experienced systemic recurrence and death. No difference was observed in DFS and OS between patients with adjuvant chemotherapy and/or adjuvant trastuzumab. In pT1b, HR(-) patients (N = 52), longer DFS was observed in patients who received adjuvant chemotherapy (p = 0.013). There was no difference in DFS according to trastuzumab treatment (p = 0.441). No difference was found according to adjuvant treatment in overall or HR(+) pT1b patients.

Conclusions

In conclusion, our result showed overall prognosis of small(<1cm), node (-), and HER2+ breast cancer and patients with pT1b and HR(-) patients can benefit from adjuvant chemotherapy. Subsequent study with large sample size is warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.